CN108348502A - 软性抗胆碱能酯的方法和组合物 - Google Patents

软性抗胆碱能酯的方法和组合物 Download PDF

Info

Publication number
CN108348502A
CN108348502A CN201680065967.5A CN201680065967A CN108348502A CN 108348502 A CN108348502 A CN 108348502A CN 201680065967 A CN201680065967 A CN 201680065967A CN 108348502 A CN108348502 A CN 108348502A
Authority
CN
China
Prior art keywords
methyl
hydroxyls
phenyl
cyclopenta
acetoxyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680065967.5A
Other languages
English (en)
Chinese (zh)
Inventor
N·S·博多尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bodor Laboratories Inc
Original Assignee
Bodor Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bodor Laboratories Inc filed Critical Bodor Laboratories Inc
Priority to CN202410181298.4A priority Critical patent/CN118021770A/zh
Priority to CN202410181300.8A priority patent/CN118021797A/zh
Priority to CN202410181296.5A priority patent/CN118045082A/zh
Publication of CN108348502A publication Critical patent/CN108348502A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680065967.5A 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物 Pending CN108348502A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202410181298.4A CN118021770A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物
CN202410181300.8A CN118021797A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物
CN202410181296.5A CN118045082A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562217362P 2015-09-11 2015-09-11
US62/217,362 2015-09-11
PCT/US2016/050385 WO2017044412A1 (en) 2015-09-11 2016-09-06 Methods and compositions for soft anticholinergic esters

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202410181296.5A Division CN118045082A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物
CN202410181298.4A Division CN118021770A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物
CN202410181300.8A Division CN118021797A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物

Publications (1)

Publication Number Publication Date
CN108348502A true CN108348502A (zh) 2018-07-31

Family

ID=58239861

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202410181296.5A Pending CN118045082A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物
CN201680065967.5A Pending CN108348502A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物
CN202410181300.8A Pending CN118021797A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物
CN202410181298.4A Pending CN118021770A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202410181296.5A Pending CN118045082A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202410181300.8A Pending CN118021797A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物
CN202410181298.4A Pending CN118021770A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物

Country Status (14)

Country Link
US (2) US11534422B2 (ja)
EP (1) EP3347007B1 (ja)
JP (4) JP7270958B2 (ja)
KR (1) KR20180061220A (ja)
CN (4) CN118045082A (ja)
AU (2) AU2016318595B2 (ja)
CA (1) CA2998357A1 (ja)
ES (1) ES2942361T3 (ja)
HK (1) HK1255558A1 (ja)
IL (1) IL257970B (ja)
MX (1) MX2018003002A (ja)
MY (1) MY197265A (ja)
WO (1) WO2017044412A1 (ja)
ZA (1) ZA201801685B (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109044965A (zh) * 2018-10-17 2018-12-21 广州大光制药有限公司 格隆溴铵的眼用药物组合物及医药用途
CN115175665A (zh) * 2020-03-03 2022-10-11 科研制药株式会社 含有索吡溴铵的药物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
US20140275204A1 (en) * 2013-03-15 2014-09-18 Bodor Laboratories, Inc. Method of dosing and use of soft anticholinergic esters

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2879100A (en) * 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
WO2001008681A1 (en) 1999-08-02 2001-02-08 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
WO2006078998A2 (en) * 2005-01-19 2006-07-27 Neurohealing Pharmaceuticals, Inc. Methods and compositions for decreasing saliva production
US7417147B2 (en) 2005-11-10 2008-08-26 Bodor Nicholas S Soft anticholinergic zwitterions
JP5257073B2 (ja) 2005-11-10 2013-08-07 ボーダー、ニコラス・エス ソフト型抗コリン作動性エステル
US8071693B2 (en) 2006-06-22 2011-12-06 Sabic Innovative Plastics Ip B.V. Polysiloxane/polyimide copolymers and blends thereof
JP2010530902A (ja) 2007-06-22 2010-09-16 サイエル ファーマ，インコーポレイティド 流涎症治療のためのグリコピロレートを含む経皮送達システム
WO2009121037A2 (en) 2008-03-27 2009-10-01 President And Fellows Of Harvard College Three-dimensional microfluidic devices

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
US20140275204A1 (en) * 2013-03-15 2014-09-18 Bodor Laboratories, Inc. Method of dosing and use of soft anticholinergic esters

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109044965A (zh) * 2018-10-17 2018-12-21 广州大光制药有限公司 格隆溴铵的眼用药物组合物及医药用途
CN115175665A (zh) * 2020-03-03 2022-10-11 科研制药株式会社 含有索吡溴铵的药物
CN115175665B (zh) * 2020-03-03 2024-04-16 科研制药株式会社 含有索吡溴铵的药物

Also Published As

Publication number Publication date
CN118021770A (zh) 2024-05-14
US11534422B2 (en) 2022-12-27
AU2021204306A1 (en) 2021-07-22
HK1255558A1 (zh) 2019-08-23
CN118045082A (zh) 2024-05-17
IL257970B (en) 2021-04-29
US11951093B2 (en) 2024-04-09
JP7270958B2 (ja) 2023-05-11
US20180250265A1 (en) 2018-09-06
EP3347007B1 (en) 2023-03-29
JP2023164671A (ja) 2023-11-10
KR20180061220A (ko) 2018-06-07
IL257970A (en) 2018-05-31
MY197265A (en) 2023-06-08
AU2016318595A1 (en) 2018-04-26
AU2016318595B2 (en) 2021-07-08
WO2017044412A1 (en) 2017-03-16
ZA201801685B (en) 2023-12-20
EP3347007A1 (en) 2018-07-18
JP2022132446A (ja) 2022-09-08
AU2021204306B2 (en) 2023-11-09
EP3347007A4 (en) 2019-05-08
US20220401410A1 (en) 2022-12-22
ES2942361T3 (es) 2023-05-31
MX2018003002A (es) 2018-08-01
CN118021797A (zh) 2024-05-14
JP2018526420A (ja) 2018-09-13
CA2998357A1 (en) 2017-03-16
JP2021001238A (ja) 2021-01-07

Similar Documents

Publication Publication Date Title
JP5941558B2 (ja) シルデナフィルを有効成分として含有し、且つ、苦味の隠蔽された高含量速溶フィルム
JP5539503B2 (ja) 不快味を効果的に隠蔽した経口用速溶フィルム
TWI554498B (zh) 置入口腔的劑型
US11517524B2 (en) Film formulations containing dexmedetomidine and methods of producing them
AU2007227614B2 (en) Solid dosage form containing a taste masked active agent
US11951093B2 (en) Methods and compositions for soft anticholinergic esters
WO2008098195A2 (en) Film comprising nitroglycerin
TW202228682A (zh) 使用右美托咪啶(dexmedetomidine)鹽酸鹽治療躁鬱症及精神病
JP2000063268A (ja) 口腔粘膜付着型徐放性錠剤及び歯周疾患治療剤
AU2016318594A1 (en) Methods and compositions for soft anticholinergic zwitterions
KR101440808B1 (ko) 실데나필 또는 이의 약제학적으로 허용되는 염을 고함량으로 포함하는 속용필름
EA045213B1 (ru) Пленочный состав, содержащий дексмедетомидин, и способ его получения
EA040771B1 (ru) Пленочные составы, содержащие дексмедетомидин, и способы их получения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination